Another frequently asked question is:

How do I get a healthcare app approved under the French PECAN reimbursement pathway?

The PECAN application process involves submitting a dossier for evaluation by French authorities. The dossier typically includes:

• Product description and intended use.
• Clinical data and supporting evidence.
• Information regarding cybersecurity and data protection.
• Interoperability documentation.
• Health-economic and organizational considerations.
• Post-market evidence generation plans.

The evaluation focuses on whether the solution is sufficiently innovative and whether early reimbursement could benefit patients and the healthcare system.

Preparation is critical. Before submitting a dossier, companies should ensure that all documentation, user interfaces, patient materials, and healthcare professional resources are fully aligned with French expectations.

This is particularly important for international companies entering France for the first time. Inconsistent terminology, poorly localized patient journeys, or unclear safety messaging can create unnecessary friction during evaluation and implementation.

A question frequently raised by market access managers is:

Can a digital therapeutic or a medical app obtain reimbursement before clinical evidence is fully established?

PECAN was specifically designed to support innovative solutions that still require additional evidence generation. However, applicants must already provide sufficient data to demonstrate the potential clinical value of the technology.

Evidence may include:

• Clinical studies.
• Real-world evidence.
• Pilot programs.
• Usability and patient engagement data.
• Organizational impact assessments.

The strength of the evidence package often determines how successfully a company can justify temporary reimbursement while additional data are collected. Companies should also ensure that clinical documentation is clearly understandable for French reviewers and stakeholders.

Terminology consistency, accurate medical language, and coherent patient communication can help reduce ambiguity and facilitate evaluation.

As digital health reimbursement becomes increasingly evidence-driven, clinical quality and documentation quality are becoming equally important.

The ultimate objective is often integration into France's long-term reimbursement framework. This means companies should view PECAN not as the final destination but as part of a broader market access strategy. Success depends not only on innovation and evidence generation but also on the ability to deploy a solution that is fully adapted to the French healthcare ecosystem.

Questions such as "Is the patient journey optimized for French users?", "Are healthcare professionals receiving clear information?", and "Is the product documentation aligned with local expectations?" can become increasingly important as adoption expands.

PECAN has created a valuable opportunity for digital therapeutics and healthcare app developers seeking early reimbursement in France. However, obtaining approval requires more than innovation alone. Companies must demonstrate regulatory compliance, clinical value, cybersecurity readiness, and a strong evidence-generation strategy.

Equally important is ensuring that the product and supporting documentation are adapted to the French healthcare environment. From patient-facing content and healthcare professional materials to terminology consistency and user experience, market readiness can play a significant role in supporting a successful PECAN strategy.

For digital health companies looking to enter the French market, a well-prepared reimbursement dossier combined with a localized and deployment-ready solution can significantly strengthen the path toward PECAN approval and long-term reimbursement success.